検索
Repligen Corp
RGENウォッチリストに追加
136.060USD
-0.940-0.69%
取引時間 （ET）15分遅れの株価
7.66B時価総額
148.95直近12ヶ月PER
詳細情報 Repligen Corp 企業名
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
Repligen Corpの企業情報
企業コードRGEN
会社名Repligen Corp
上場日Apr 29, 1986
最高経営責任者「CEO」Loeillot (Olivier)
従業員数1778
証券種類Ordinary Share
決算期末Apr 29
本社所在地Building 1, Suite 100
都市WALTHAM
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号02453
電話番号17814499560
ウェブサイトhttps://www.repligen.com/
企業コードRGEN
上場日Apr 29, 1986
最高経営責任者「CEO」Loeillot (Olivier)
Repligen Corpの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Ms. Karen A. Dawes
Ms. Karen A. Dawes
Lead Independent Director
Lead Independent Director
92.82K
+1.07%
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
40.05K
+8.56%
Mr. Ralf Kuriyel
Mr. Ralf Kuriyel
Senior Vice President - Research and Development
Senior Vice President - Research and Development
9.42K
-28.60%
Mr. Nicolas M. Barthelemy
Mr. Nicolas M. Barthelemy
Independent Director
Independent Director
5.44K
+18.30%
Mr. Rohin Mhatre, Ph.D.
Mr. Rohin Mhatre, Ph.D.
Independent Director
Independent Director
5.01K
+19.84%
Mr. Olivier Loeillot
Mr. Olivier Loeillot
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.22K
-155.54%
Mr. Tony John Hunt
Mr. Tony John Hunt
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Ms. Carrie Eglinton Manner
Ms. Carrie Eglinton Manner
Independent Director
Independent Director
--
--
Mr. James R. Bylund
Mr. James R. Bylund
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Konstantin Konstantinov, Ph.D.
Dr. Konstantin Konstantinov, Ph.D.
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Ms. Karen A. Dawes
Ms. Karen A. Dawes
Lead Independent Director
Lead Independent Director
92.82K
+1.07%
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
40.05K
+8.56%
Mr. Ralf Kuriyel
Mr. Ralf Kuriyel
Senior Vice President - Research and Development
Senior Vice President - Research and Development
9.42K
-28.60%
Mr. Nicolas M. Barthelemy
Mr. Nicolas M. Barthelemy
Independent Director
Independent Director
5.44K
+18.30%
Mr. Rohin Mhatre, Ph.D.
Mr. Rohin Mhatre, Ph.D.
Independent Director
Independent Director
5.01K
+19.84%
Mr. Olivier Loeillot
Mr. Olivier Loeillot
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.22K
-155.54%
よくある質問
Repligen Corpの上位5名の株主は誰ですか？
Repligen Corpの上位5名の株主は以下のとおりです。Ms. Karen A. Dawes
Repligen Corp（RGEN）の株式を保有している機関の数はいくつですか？
2026Q1時点で、Repligen Corpの株式を保有している機関は1067社あり、保有株式の総市場価値は約65.93Mで、全体の116.89%を占めています。2025Q4と比較して、機関の持ち株は-2643397.00増加しています。
Repligen Corpの最大の収益源は何ですか？
2026Q1において、Product revenue - Filtration products部門がRepligen Corpにとって最大の収益を生み出しており、その金額は402.79Mで、全収益の54.58%を占めています。
